181 related articles for article (PubMed ID: 22569351)
1. Is there a role for therapeutic drug monitoring with codeine?
Kelly LE; Madadi P
Ther Drug Monit; 2012 Jun; 34(3):249-56. PubMed ID: 22569351
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
[TBL] [Abstract][Full Text] [Related]
3. Observations on the urine metabolic profile of codeine in pain patients.
Yee DA; Atayee RS; Best BM; Ma JD
J Anal Toxicol; 2014 Mar; 38(2):86-91. PubMed ID: 24396053
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
Crews KR; Gaedigk A; Dunnenberger HM; Klein TE; Shen DD; Callaghan JT; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2012 Feb; 91(2):321-6. PubMed ID: 22205192
[TBL] [Abstract][Full Text] [Related]
5. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
Crews KR; Gaedigk A; Dunnenberger HM; Leeder JS; Klein TE; Caudle KE; Haidar CE; Shen DD; Callaghan JT; Sadhasivam S; Prows CA; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2014 Apr; 95(4):376-82. PubMed ID: 24458010
[TBL] [Abstract][Full Text] [Related]
6. Codeine and opioid metabolism: implications and alternatives for pediatric pain management.
Chidambaran V; Sadhasivam S; Mahmoud M
Curr Opin Anaesthesiol; 2017 Jun; 30(3):349-356. PubMed ID: 28323671
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.
Gammal RS; Crews KR; Haidar CE; Hoffman JM; Baker DK; Barker PJ; Estepp JH; Pei D; Broeckel U; Wang W; Weiss MJ; Relling MV; Hankins J
Pediatrics; 2016 Jul; 138(1):. PubMed ID: 27335380
[TBL] [Abstract][Full Text] [Related]
8. Pain management in the 21st century: utilization of pharmacogenomics and therapeutic drug monitoring.
Jannetto PJ; Bratanow NC
Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):745-52. PubMed ID: 21585291
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.
Haufroid V; Hantson P
Clin Toxicol (Phila); 2015 Jul; 53(6):501-10. PubMed ID: 25998998
[TBL] [Abstract][Full Text] [Related]
10. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?
Lötsch J; Rohrbacher M; Schmidt H; Doehring A; Brockmöller J; Geisslinger G
Pain; 2009 Jul; 144(1-2):119-24. PubMed ID: 19395173
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice.
Carranza-Leon D; Dickson AL; Gaedigk A; Stein CM; Chung CP
Pharmacogenomics J; 2021 Aug; 21(4):484-490. PubMed ID: 33750887
[TBL] [Abstract][Full Text] [Related]
12. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management.
Jannetto PJ; Bratanow NC
Pharmacogenomics; 2009 Jul; 10(7):1157-67. PubMed ID: 19604091
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study.
Madadi P; Ross CJ; Hayden MR; Carleton BC; Gaedigk A; Leeder JS; Koren G
Clin Pharmacol Ther; 2009 Jan; 85(1):31-5. PubMed ID: 18719619
[TBL] [Abstract][Full Text] [Related]
14. Variability in the frequency of cytochrome P450-2D6 (CYP2D6) deficiency.
Mörike K; Platten HP; Mikus G; Klotz U
Br J Clin Pharmacol; 1998 Jul; 46(1):87. PubMed ID: 9690955
[No Abstract] [Full Text] [Related]
15. Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics.
Zahari Z; Ismail R
Drug Metab Pharmacokinet; 2014; 29(1):29-43. PubMed ID: 23759977
[TBL] [Abstract][Full Text] [Related]
16. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study.
Willmann S; Edginton AN; Coboeken K; Ahr G; Lippert J
Clin Pharmacol Ther; 2009 Dec; 86(6):634-43. PubMed ID: 19710640
[TBL] [Abstract][Full Text] [Related]
17. Variable cytochrome P450 2D6 expression and metabolism of codeine and other opioid prodrugs: implications for the Australian anaesthetist.
Wilcox RA; Owen H
Anaesth Intensive Care; 2000 Dec; 28(6):611-9. PubMed ID: 11153286
[TBL] [Abstract][Full Text] [Related]
18. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.
Lötsch J; Skarke C; Liefhold J; Geisslinger G
Clin Pharmacokinet; 2004; 43(14):983-1013. PubMed ID: 15530129
[TBL] [Abstract][Full Text] [Related]
19. The pharmacogenetics of codeine hypoalgesia.
Sindrup SH; Brøsen K
Pharmacogenetics; 1995 Dec; 5(6):335-46. PubMed ID: 8845855
[TBL] [Abstract][Full Text] [Related]
20. Codeine, ultrarapid-metabolism genotype, and postoperative death.
Ciszkowski C; Madadi P; Phillips MS; Lauwers AE; Koren G
N Engl J Med; 2009 Aug; 361(8):827-8. PubMed ID: 19692698
[No Abstract] [Full Text] [Related]
[Next] [New Search]
